Cytori Therapeutics Inc (NASDAQ:CYTX) up by 2.80%, Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

Posted by Steve Raasch May 21, 2013 0 Comment 1070 views


Cytori Therapeutics Inc (NASDAQ:CYTX): In Tuesday’s trading session, Cytori Therapeutics Inc (NASDAQ:CYTX) jumped 2.80%. Its opening price of $2.51 rose to touch an intraday high of $2.58 and eventually headed down to currently trade at $2.57 per share. Over 0.101 million shares exchanged hands in the current trading session. This number stood below the average volume of 0.235 million that was measured over a 30-day period.

CYTX develops cell-therapies that are based on autologous adipose-derived stem and also on regenerative cells (ADRCs). These are used in the treatment of cardiovascular diseases and to repair soft-tissue defects. The advanced therapeutic application in Cytori Therapeutics Inc (NASDAQ:CYTX)’s clinical pipeline is for the treatment of cardiovascular disease. Its products include Puregraft, Celbrush and Cytori LipoBank. Celbrush is available in 10-milliliter and 3-milliliter sizes. It is used in tandem with a Soft-Ject Syringe in a corresponding size. Puregraft has been developed for autologous fat-grafting as well as aesthetic body contouring. This is available in two sizes: 250-milliliter that processes 50-250milliliter of tissue. The other is the 850 milliliter one which processes 200-850milliliter of tissue. Cytori LipoBank is a GTP-compliant cryo-preservation system. This long-term, storage option is for viable adipose tissue. It is used after a single liposuction.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH): In Tuesday’s trading session, Anthera Pharmaceuticals Inc (NASDAQ:ANTH) jumped 0.59%. Its opening price of $0.91 was also the intraday high, which eventually headed down to currently trade at $0.583 per share. Over 0.149 million shares exchanged hands in the current trading session. This number stood below the average volume of 0.650 million that was measured over a 30-day period.

ANTH is a development-stage, bio-pharma company that is focused on the development and commercialization of products that are used in the treatment of diseases that are associated with inflammation. As of 31 December 2011, it had one, Phase II clinical program named blisibimod. Two of the company’s product candidates, varespladib sodium and varespladib have been designed to inhibit secretory phospholipase A2 (sPLA2), an enzyme target. This has been implicated in a variety of acute-inflammatory conditions. These include acute chest syndrome and acute coronary syndrome which are associated with sickle-cell disease. They are also used in chronic diseases such as stable coronary artery disease (CAD). In addition to these, blisibimod targets the B-lymphocyte stimulator (BLyS).


About Steve Raasch

Steve Raasch is a breaking news reporter for GDP insider. During his nearly two decades of editorial experience, Steve has covered a variety of topics including small business, health, personal finance, advertising, workplace issues and consumer behavior. Steve is very passionate about his work. Steve earned a master of arts degree in international relations from the Johns Hopkins University School of Advanced International Studies in Washington.

View all post by Steve Raasch Visit author's website

Write Your Comment

Breaking News + Trend Analysis Reports Delivered To Your Inbox!

Free Exclusive Offer [Limited-Time]

Enter your email to continue reading our article! As a bonus to you, receive a FREE TREND ANALYSIS REPORT on ANY COMPANY as well as hot stock alerts.